Mirogabalin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain
Conditions
Diabetic Peripheral Neuropathic Pain
Trial Timeline
Sep 18, 2019 → Jan 24, 2022
NCT ID
NCT04094662About Mirogabalin + Placebo
Mirogabalin + Placebo is a phase 3 stage product being developed by Daiichi Sankyo for Diabetic Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04094662. Target conditions include Diabetic Peripheral Neuropathic Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04094662 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| Ruboxistaurin mesylate | Eli Lilly | Phase 3 | 77 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg | Yuhan | Approved | 85 |
| Anplag(Sarpogrelate) + Placebo | Yuhan | Approved | 85 |
| CS-3150 + placebo | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule | Daiichi Sankyo | Phase 2 | 52 |
| olmesartan medoxomil + Placebo Tablets | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Beraprost sodium | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |